Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucentis after vitrectomy and subretinal rtPA for acute submacular hemorrhage in exudative AMD
DRKS00005090Phase 2Recruiting
- Sponsor
- Universitätsklinikum Schleswig-Holstein
- Start
- Dec 2013
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ranibizumab in age-related macular degeneration (AMD), retinal hemorrhage (RH) and submacular hemorrhage (SMH), sponsored by Universitätsklinikum Schleswig-Holstein. Started Dec 2013; status: recruiting.
02
Drugs
ranibizumab
03
Conditions
age-related macular degeneration (AMD)retinal hemorrhage (RH)submacular hemorrhage (SMH)
Beyond the preview
Go deeper on DRKS00005090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00005090.